138676-18-3

Basic information

• Product Name: 4-Oxazolecarboxylic acid, 5-ethyl-2-phenyl-
• CAS NO: 138676-18-3
• Molecular Formula: C12H11NO3
• Molecular Weight: 217.224
• Mol File: 138676-18-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-Oxazolecarboxylic acid, 5-ethyl-2-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Oxazolecarboxylic acid, 5-ethyl-2-phenyl-(138676-18-3)
• EPA Substance Registry System: 4-Oxazolecarboxylic acid, 5-ethyl-2-phenyl-(138676-18-3)

Safety Data

• Hazardous Substances Data: 138676-18-3(Hazardous Substances Data)

Upstream product

• 98-88-4 benzoyl chloride 
• 1229419-49-1 2-benzoylamino-4-methyl-3-oxo-butanoic acid benzyl ester 
• 1319747-26-6 C₂₅H₂₃NO₃ 
• 1229419-50-4 5-ethyl-2-phenyl-oxazole-4-carboxylic acid benzyl ester 
• 18735-74-5 5-methyl-2-phenyloxazole-4-carboxylic acid 
• 74-88-4 methyl iodide 

Downstream Products

• 1229419-52-6 4-{4-[(2-phenyl-5-ethyl-oxazole-4-carbonyl)-amino]-phenyl}-piperidine-1-carboxylic acid tert-butyl ester 
• 1229419-51-5 2-phenyl-5-ethyl-oxazole-4-carboxylic acid (4-piperidin-4-yl-phenyl)-amide 

Relevant articles and documents

Discovery and optimization of 2-phenyloxazole derivatives as diacylglycerol acyltransferase-1 inhibitors

In a discovery effort to find safe and effective DGAT-1 inhibitors, we have identified 2-phenyloxazole 4-carboxamide 1 as a conformationally constrained analog of a hydrazide hit, which was previously identified from high-throughput screening. Further optimization of this series has led to chemically more stable 2-phenyloxazole-based DGAT-1 inhibitor 25 with improved solubility, cell-based activity, and pharmacokinetic properties. Compound 25 also demonstrated in vivo efficacy in a diet-induced obesity (DIO) rat model.

Diacylglycerol acyltransferase inhibitors

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.